Can a PET scan predict if immunotherapy works? new study aims to find out
NCT ID NCT07448727
First seen Mar 05, 2026 · Last updated Jun 19, 2026 · Updated 17 times
Summary
This study is testing whether a special PET scan taken 6 weeks after starting pembrolizumab (an immunotherapy drug) can predict how well the drug works at 3, 6, and 9 months in people with advanced head and neck cancer. Researchers will enroll 25 patients whose cancer has returned or spread and who have a specific marker (PD-L1 CPS >1). The goal is to see if early changes in tumor activity on the scan can guide treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD & NECK CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tor Vergata University Hospital
RECRUITINGRome, Italy, 00133, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab
What this could lead to
If successful, this could help doctors know sooner whether pembrolizumab is working, allowing them to adjust treatment earlier.
What could go wrong
This is a small, early observational study (25 people) that only looks at scans, not a new treatment. It may not lead to changes in care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.